logo banner home news contact
nav
space about argos space
argos overview
market opportunities
leadership
current investors
partners
space

 

Market Opportunities

FOCUS ON CANCER AND HIV
Argos’ initial focus is on cancer and HIV. Argos’ personalized immunotherapeutics are applicable to nearly all cancers, including hematologic malignancies, and to the majority of new cancer patients.

Argos’ personalized immunotherapy approach could enable a more effective and potentially safer treatment option to a large percentage of patients around the globe. The Company estimates that a personalized immunotherapy product to treat cancers and/or HIV could have multi-billion dollar revenue potential.

FOCUS ON OTHER INFECTIOUS DISEASES
Beyond HIV, Argos’ patented technology offers the potential to create personalized immunotherapies for other infectious diseases resistant to current therapies. Chronic infections such as hepatitis C (HCV) represent some of the largest and most significant areas of unmet medical need.

FOCUS ON TRANSPLANTATION AND Inflammatory and AUTOIMMUNE DISORDERS
Through its proprietary expertise in the biology of dendritic cells, Argos has recognized potential applications for other disease areas. Argos is developing soluble CD83 protein as a novel first-in-class therapy to prevent transplantation rejection and treat certain inflammatory and autoimmune diseases. According to the Organ Procurement and Transplantation Network, about 25,000 organ transplants take place per year. The rate of transplant rejection varies by organ and ranges from 30 to 60 percent, creating a considerable need for effective prevention and treatment. Current transplant rejection treatment includes immunosuppressive agents with heavy side effects. In contrast, Argos’ CD83 protein selectively blocks immunoresponse without causing total immunosuppression. In addition to transplantation rejection, CD83 is potentially a treatment for a number of inflammatory and autoimmune diseases, including irritable bowel disease, multiple sclerosis and diabetes, for which there are large unmet medical needs. Argos is developing its anti-Interferon-alpha monoclonal antibody for the treatment of systemic lupus erythematosus (SLE) for which there is a clear large unmet medical need.